On the Couch with Dr Chris Burns (ASX: ATX): Pancreatic Cancer, Lilly and the Next Trial

In this episode of On the Couch , Henry Jennings speaks with Dr Chris Burns , CEO and Managing Director of Amplia Therapeutics (ASX: ATX). ATX features in one of Marcus Today's biotech baskets. Chris explains how narmafotinib, Amplia's lead drug candidate, came out of a Melbourne research centre, what the clinical study in metastatic pancreatic cancer has shown so far, and the plan for a larger, placebo-controlled registrational trial. They also cover the collaboration with Eli Lilly, the potential to expand into other tumour types such as lung and ovarian, where AI is helping the development process, and the risks investors should weigh at this stage. — Marcus Today – Daily Market Insights Marcus Today provides clear, practical commentary for self-directed investors – covering markets, portfolios, education, and decision-making without the noise. If you'd like to go further: Start a free 14-day trial of Marcus Today https://marcustoday.com.au/trial-sign-up/?utm_source=podcast&utm_medium=audio&utm_campaign=free-trial Join Marcus Today Use code MTPODCAST for 10% off. https://marcustoday.com.au/sign-up/?pc=MTPODCAST&utm_source=podcast&utm_medium=audio&utm_campaign=sign-up MT20 – Managed ETF Portfolio A professionally managed portfolio run by Marcus Padley and the team, using ASX-listed ETFs with active market timing. https://marcustoday.com.au/managed-portfolios/?utm_source=podcast&utm_medium=audio&utm_campaign=mt20-info Principles – How We Think About Investing A short video series on timing, behaviour, and decision-making. No stock tips. https://marcustoday.com.au/mini-series-principles-sign-up/?utm_source=podcast&utm_medium=audio&utm_campaign=principles-mini-series — Disclaimer This podcast is general information only and does not consider your personal circumstances. It is not personal financial advice.